Project Topic
Finance
Blog
News
Scholarship
Books
Tutor
...
Everything
Local
Politics
Business
Finance
Sports
Entertainment
Lifestyle
Technology
Education
World
Health
Sign Up
Login
Ozempic quells kidney disease risk, study finds
8 months ago
46
In a yearslong trial of more than 3,500 participants, Novo Nordisk's Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death.
View Entire Post
Read Entire Article
Homepage
Health
Ozempic quells kidney disease risk, study finds
Related
Most Americans Blame Insurance Profits and Denials Alongside Killer in UHC CEO Death, Poll Finds
3 weeks ago
Ambient Listening on the Front End; AI & Automation on the Back End Poised to Improve RCM, KLAS Finds
4 weeks ago
Is Work Stress Putting Your Blood Pressure at Risk?
4 weeks ago
Case Study: How Serge Crismale Ditched the 9-5 for a Thriving Franchise
4 weeks ago
Best Courses to Study in Australia: A Roadmap for Indian Students
4 weeks ago
Agave, the startup behind Find the Cat, finds $18M
4 weeks ago
More News From Beckers Hospital Review
What Amazon pays for 7 healthcare-related jobs
4 weeks ago
Florida health system eyes 2025 as 'year of innovation' after Epic go-live
4 weeks ago
New York cancer center opens $98M cell, gene therapy hub
4 weeks ago
UPMC hospital names CNO
a month ago
HHS extends COVID vaccine liability protection through 2029
a month ago
GLP-1s and heart outcomes: 5 recent findings
a month ago
Trending
1.
John Fetterman
2.
Karen Read
3.
Florida Panthers
4.
Georgia baseball
5.
Malawi
6.
Tony Evans
7.
Rebecca Grossman
8.
iOS 18 beta
9.
Maren Morris
10.
Nvidia stock price
Popular
Happy Holiday!
3 weeks ago
That Crazy Expensive Arc Pulse Bumper Case is Coming to the Pixel 9 Series
2 weeks ago
Top AI course builders to help you publish your content fast in 2025
3 weeks ago
7 Red Flags that say “Quit your Job”
4 weeks ago
TFVC: 2024 Year in Review
2 weeks ago
The 36th Annual National Service-Learning Conference® Returns to Saint Paul, MN
4 weeks ago